Under construction – not a live service

Skip to content

Frontlight Research

Institution

Peking University First Hospital

Beijing, ChinaWebsite

Also known as: Beida Hospital

285running trials
91closed trials
25,776publications (OpenAlex)

Running trials

Not yet recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· Phase 3· Eli Lilly and Company· Source
Recruiting
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07629583· Phase 1· Genentech, Inc.· Source
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
NCT07923058· Beijing Pins Medical Co., Ltd· Source
Not yet recruiting
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
NCT07886476· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· Phase 3· Hoffmann-La Roche· Source
Recruiting
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
NCT07323095· Phase 2· Atom Therapeutics Co., Ltd· Source
Not yet recruiting
68Ga- and 18F-CAIX PET Imaging Study
NCT07875946· Early phase 1· Peking University First Hospital· Source
Not yet recruiting
Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
NCT07887321· Shanghai East Hospital· Source
Not yet recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
NCT07848880· Phase 2· Zhejiang Doer Biologics Co., Ltd.· Source
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Not yet recruiting
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188· Phase 3· Zhao Minghui· Source
Recruiting
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
NCT07039474· Peking University First Hospital· Source
Recruiting
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
NCT07793019· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
NCT07653685· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Not yet recruiting
Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma
NCT07686744· Phase 1· Jian Lin· Source
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
NCT07795437· Peking University First Hospital· Source
Recruiting
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
NCT07822100· Hong Zhang· Source
Recruiting
DEC003M in Prostate Cancer
NCT07657806· Phase 1· Hangzhou DAC Biotechnology Co., Ltd.· Source
Not yet recruiting
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
NCT07730632· Phase 2· Qilu Pharmaceutical Co., Ltd.· Source
Recruiting
Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction
NCT07693049· Peking University Third Hospital· Source
Recruiting
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
NCT07468851· Phase 1/2· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source
Not yet recruiting
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861· Phase 4· Peking University First Hospital· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
NCT07554924· Phase 1/2· Lanyue Biotech (Hangzhou) Co., Ltd.· Source
Recruiting
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
NCT07424287· Phase 3· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source
Not yet recruiting
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source
Recruiting
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
NCT07875959· Peking University First Hospital· Source
Recruiting
Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
NCT07733024· Phase 2· Tingting Yuan· Source
Recruiting
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
NCT07582133· Phase 2· Chengdu Suncadia Medicine Co., Ltd.· Source
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source
Recruiting
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
NCT07660939· Phase 1· Peking University First Hospital· Source
Recruiting
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
NCT07781124· Vantive Health LLC· Source
Recruiting
hUC-MSC-Exosomes for T2DM - Safety & Efficacy
NCT07693036· Phase 1/2· Peking University First Hospital· Source
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654· Phase 2· R1 Therapeutics· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
NCT07528027· Phase 3· Shandong Suncadia Medicine Co., Ltd.· Source
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· Phase 1· Shanghai Henlius Biotech· Source
Recruiting
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
NCT07614477· Phase 2· Everest Medicines (China) Co.,Ltd.· Source
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
NCT07607275· Phase 4· Beijing Anzhen Hospital· Source
Recruiting
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
NCT07498907· Phase 3· Peking University First Hospital· Source
Recruiting
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NCT07557225· Peking University First Hospital· Source
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
NCT07450599· Phase 2· Bayer· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· BioNTech SE· Source
Recruiting
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123· Phase 3· Haisco Pharmaceutical Group Co., Ltd.· Source
Not yet recruiting
Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma
NCT07504939· Peking University First Hospital· Source
Recruiting
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
NCT07774533· Early phase 1· Peking University First Hospital· Source
Recruiting
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT07465263· Phase 3· CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.· Source
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626· Phase 3· Sun Yat-sen University· Source

Showing 50 of 285.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
Development and Validation of a KAP Questionnaire for Secondary Hypertension: Evaluating a Community Short-Video Intervention in Rural Beijing
NCT07497841· Peking University First Hospital· Source
Recruiting
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
NCT07616700· Phase 2· Haisco Pharmaceutical Group Co., Ltd.· Source
Terminated
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
NCT07100938· Phase 2· BeiGene· Source
Completed
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
NCT07073170· Phase 1· Eli Lilly and Company· Source
Completed
To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.
NCT07403565· Suzhou Hechun Medical Technology Co., Ltd.· Source
Completed
A Phase IIa Study in Primary IgA Nephropathy Patients
NCT07634744· Phase 2· Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.· Source
Completed
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
NCT07704697· Phase 3· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source
Completed
Prospective, Multicenter, Self-controlled Clinical Trial to Validate Optical Ultrasonic Flow Ratio (OUFR)
NCT06726252· Harbin Medical University· Source
Completed
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT06670352· Phase 2· Haisco Pharmaceutical Group Co., Ltd.· Source
Withdrawn
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
NCT06598631· Phase 2· Eli Lilly and Company· Source
Completed
Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia in Patients at High-risk of OSA
NCT06566482· Phase 4· Peking University First Hospital· Source
Completed
A Study of ZT002 Injection With Subjects With Overweight or Obesity
NCT07020884· Phase 2· Beijing QL Biopharmaceutical Co.,Ltd· Source
Completed
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
NCT07020949· Phase 1· Tonghua Dongbao Pharmaceutical Co.,Ltd· Source
Completed
Evaluation of Transrectal Perilesional Biopsy in Diagnosis of Prostate Cancer
NCT06482658· Peking University First Hospital· Source
Completed
Blood Biomarkers for Screening of Alzheimer's Disease
NCT06477484· Peking University First Hospital· Source
Completed
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
NCT06421740· AbbVie· Source
Completed
Effects of Exercise During Pregnancy on the Long-term Metabolic Health of Mothers and Their Offspring
NCT07435857· Peking University First Hospital· Source
Completed
the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human
NCT06490263· Phase 1· Beijing Wehand-Bio Pharmaceutical Co., Ltd· Source
Completed
Comprehensive Evaluation of MRI-AI in Prostate Cancer Diagnosis
NCT06575361· Peking University First Hospital· Source
Completed
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
NCT07386717· Peking University First Hospital· Source
Withdrawn
Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
NCT06176235· Phase 2· Peking University People's Hospital· Source
Completed
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
NCT06139393· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Completed
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
NCT06122649· Phase 3· Amgen· Source
Completed
A Clinical Study of TQH2929 in Healthy Adult Subjects
NCT06156280· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
NCT06003218· Peking University First Hospital· Source
Completed
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
NCT06048588· Phase 1/2· Beijing Inno Medicine Co., Ltd.· Source
Completed
A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain
NCT06076486· Phase 3· Nanjing Chia-tai Tianqing Pharmaceutical· Source
Completed
Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial
NCT06362291· Peking University First Hospital· Source
Completed
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
NCT07704684· Phase 3· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897· Phase 3· Takeda· Source
Completed
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627· Phase 3· AbbVie· Source
Completed
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
NCT07030595· Phase 3· Alebund Pharmaceuticals· Source
Completed
A Study of HS-20094 in T2DM Participants
NCT06118008· Phase 2· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source
Completed
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System
NCT05641207· Energenx Medical LTD.· Source
Terminated
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
NCT05760703· Phase 2· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Terminated
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
NCT05760781· Phase 2· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Completed
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
NCT05819398· Phase 2/3· Boehringer Ingelheim· Source
Completed
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
NCT05763823· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Software-delivered CBT-I for Insomnia Disorder
NCT05747963· Peking University Sixth Hospital· Source
Completed
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
NCT05534919· Phase 3· Everest Medicines (Singapore) Pte. Ltd.· Source
Completed
TESTING -ON Post-Trial ObservatioNal Cohort Study
NCT05434325· The George Institute· Source
Completed
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
NCT05546476· Phase 2· Pfizer· Source
Completed
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
NCT05590793· Phase 3· Ipsen· Source
Completed
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203· Phase 3· Abivax S.A.· Source
Completed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231· Phase 2/3· Hutchmed· Source
Completed
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167· Phase 2/3· argenx· Source
Completed
A Trial of HR17031 Injection With Renal Insufficiency
NCT05292495· Phase 1· Jiangsu HengRui Medicine Co., Ltd.· Source

Showing 50 of 91.

Registry name variants (39)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Peking University First Hospital
Beijing, 100034
321 trials
Departmeng of Urology, Peking University First Hospital
Beijing
7 trials
Department of Radiotherapy Oncology, Peking University First Hospital
Beijing, Beijing Municipality 100034
6 trials
Peking University First Hospital - Changqiao Campus
Beijing, 100034
4 trials
Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital
Beijing, Beijing Municipality 100034
3 trials
- NCT05576766Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
  Contact: Dong-Xin Wang, MD, PhD
- NCT07088874Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy
  Contact: Dong-Xin Wang, MD, PhD
- NCT04209218Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
  Contact: Dong-Xin Wang, MD, PhD
Department of Nuclear Medicine, Peking University First Hospital
Beijing, Beijing Municipality 010000
3 trials
- NCT0787594668Ga- and 18F-CAIX PET Imaging Study
  Contact: Tingting Yuan, M.D.
- NCT07733024Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
  Contact: Tingting Yuan, MD
- NCT06717113A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
  Contact: Tianyao Wang, Ph.D.
Peking University First Hospital (Beida Hospital)
Beijing, Beijing Municipality 100034
3 trials
- NCT06908226A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
- NCT06719141A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
- NCT06660394A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Department of Urology, Peking University First Hospital, Beijing, 100034
Beijing
2 trials
- NCT07319923Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
  Contact: Zheng Zhang
- NCT07282223Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism
Peking University First Hospital
Xicheng, Beijing Municipality
2 trials
- NCT03657732The Chinese Familial Alzheimer's Network
  Contact: Zhirong Jia
- NCT03653156China Cognition and Aging Study
  Contact: Zhirong Jia
Peking University First Hospital - Daxing Campus
Beijing, 100034
2 trials
- NCT05066217An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
  Contact: Yuwu Jiang (principal investigator)
- NCT04462770A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
  Contact: Yuwu Jiang (principal investigator)
Peking University， First Hospital, Department of Pediatrics
Beijing, 100034
2 trials
- NCT05901987Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
- NCT05824169Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
  Contact: Yanbin Fan
Peking University First Hospital - Oncology Department
Beijing, Beijing Municipality 100034
2 trials
- NCT06760819A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- NCT05794906A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
The first hospital of Peking University
Beijing
2 trials
- NCT07319065Left Ventricular Myocardial Work for Predicting Response to CRT
  Contact: Ying Yang
- NCT06044350A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Department of Medical Oncology, Peking University First Hospital
Beijing
1 trial
- NCT06120374Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
  Contact: Shikai Wu, M.D.
Department of Urology, Peking University First Hospital
Beijing, 100034
1 trial
- NCT07111364Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study
  Contact: Zheng Zhang
Division of Cardiology, Peking University First Hospital
Beijing, Beijing Municipality 100034
1 trial
- NCT06489080Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction
  Contact: Jia Jia
First Hospital of Peking University
Beijing, 100034
1 trial
- NCT03987308Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
  Contact: Geheng Yuan, Ph.D. M.D.
Peking University First Hospital
Beijin, Bejing 100034
1 trial
- NCT04532606Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
  Contact: Wang Dong-Xin, MD, PhD
Peking University First Hospital
Dongcheng District, 100009
1 trial
- NCT07073170A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
Peking University First Hospital, Beijing,
Beijing
1 trial
- NCT07166445Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
  Contact: Peking University First Hospital Peking University First Hospital
Peking University First Hospital(Daxing Area) (Site 0838)
Beijing, Beijing Municipality 102627
1 trial
- NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
  Contact: Study Coordinator
Peking University First Hospital (First Clinical Medical School of Peking University)
Beijing, Beijing Municipality 100034
1 trial
- NCT07283835Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
  Contact: Zhisong He
Peking University First Hospital /ID# 250517
Beijing, Beijing Municipality 100034
1 trial
- NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Peking University First Hospital /ID# 252392
Beijing, Beijing Municipality 100034
1 trial
- NCT05814627Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Peking University First Hospital /ID# 259816
Beijing, Beijing Municipality 100034
1 trial
- NCT06191744Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Peking University First Hospital /ID# 274865
Beijing, Beijing Municipality 100034
1 trial
- NCT06421740An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
Peking University First Hospital (Site 0009)
Beijing, Beijing Municipality 100034
1 trial
- NCT05763823A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
Peking University First Hospital (Site 0184)
Beijing, Beijing Municipality 100034
1 trial
- NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
  Contact: Study Coordinator
Peking University First Hospital (Site 0723)
Beijing, Beijing Municipality 100034
1 trial
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Peking University First Hospital (Site 0726)
Beijing, Beijing Municipality 100034
1 trial
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Peking University First Hospital (Site 0800)
Beijing, Beijing Municipality 100034
1 trial
- NCT04934722Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
Peking University First Hospital (Site 1434)
Beijing, Beijing Municipality 100034
1 trial
- NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  Contact: Study Coordinator
Peking University First Hospital (Site 1759)
Beijing, Beijing Municipality 100034
1 trial
- NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Peking University First Hospital - Site #20
Beijing, Beijing Municipality 100034
1 trial
- NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Peking University First Hospital (Site 2022)
Beijing, Beijing Municipality 100034
1 trial
- NCT06136559A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
  Contact: Study Coordinator
Peking University First Hospital (Site 2511)
Beijing, Beijing Municipality 100034
1 trial
- NCT07176390A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Peking University First Hospital (Site 6011)
Beijing, Beijing Municipality 100034
1 trial
- NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Peking University First Hospital / Urology Department
Beijing, 100034
1 trial
- NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Rheumatology and Immunology department, Peking University First Hospital
Beijing, Xicheng District 100034
1 trial
- NCT03138941Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
  Contact: Zhuoli Zhang

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 02z1vqm45 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – Peking University First Hospital: trials and research groups – Frontlight Research